Linked Life Data

9238816

Source:http://linkedlifedata.com/resource/pubmed/id/9238816

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
11
pubmed:dateCreated
1997-8-21
pubmed:abstractText
Treatment of epithelial ovarian cancer is based mainly on surgery and chemotherapy. Indications of chemotherapy depends on stage of disease and tumor histology. Initial polychemotherapy must be a platinum compound based regimen with respect of dose-intensity. Up to now the initial standard chemotherapy is a cyclophosphamide and platinum combination. Only one randomized study comparing cisplatin-cyclophosphamide and cisplatin-Taxol has been published in patients with macroscopic residual disease (> 1 cm). The improvement of survival with Taxol has led to propose this association as standard treatment in the USA and in some European countries. The place and role of anthracyclines are discussed. New drugs (topotecan, Oxaliplatine) and new modalities of administration (intensification, intraperitoneal route) are currently under evaluation.
pubmed:language
fre
pubmed:journal
pubmed:citationSubset
F
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0035-2640
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
47
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1205-10
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1997
pubmed:articleTitle
[First line chemotherapy of epithelial cancers of the ovary].
pubmed:affiliation
Institut Gustave-Roussy, Viliejuif.
pubmed:publicationType
Journal Article, English Abstract, Review